Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.

Cheng-Hsuan TsaiChi-Chao ChaoSung-Tsang HsiehAn-Li YuYuan-Kun Aden WuMei-Fang ChengMing-Jen LeeChia-Hung ChouChia-Tung ShunHsueh-Wen HsuehJimmy Jyh-Ming JuangPing-Huei TsengMao-Yuan SuYen-Hung Lin

Published in: Orphanet journal of rare diseases (2023)

After a one-year treatment period, tafamidis exhibited subtle but statistically significant reductions in ECV, potentially indicating a decrease in amyloid deposition among patients diagnosed with hereditary A97S ATTR-CM.

Keyphrases

heart failure
left ventricular
multiple myeloma
wild type